Navigation Links
Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
Date:9/11/2012

peline candidate," said Travis E. Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "We look forward to the results of the pivotal registration studies for HP802-247 and, ultimately, to bringing a significant advance in the treatment of venous leg ulcers to the millions of patients suffering from this debilitating condition."

For more information about the HP802-247 North American clinical trial, go to www.LegSoreStudy.com, or call 866-910-2020 to speak with a clinical trial recruitment specialist.

About HP802-247

HP802-247 is an investigational allogeneic living human cell bioformulation that consists of two components that are sprayed sequentially on the wound bed at the time of treatment: a fibrinogen solution and a cell preparation containing a mixture of growth arrested, living, allogeneic epidermal keratinocytes and dermal fibroblasts.

Based on in vitro studies, HP802-247 is believed to release various growth factors and cytokines into the micro-environment of the wound. These living cells are anticipated to interact with the patient's own cells to stimulate wound healing.  HP802-247 has been designed to deliver a defined cell ratio (keratinocyte:fibroblasts) to support optimal tissue regeneration.

Positive results for a Phase IIb clinical trial investigating the efficacy of HP802-247 in venous leg ulcers were recently published in The Lancet. The study was a randomized, double blind, dose-finding study involving 228 subjects enrolled across 35 investigational centers in the United States and Canada. Overall, HP802-247 achieved statistical significance, as compared with control plus standard care, in both the primary and secondary endpoints. HP802-247 was generally well tolerated in the study with the most frequently reported adverse events being skin ulcers, cellulitis, wound infection, and skin irritation.  The safety profile of
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
2. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
5. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
6. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
7. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
8. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
9. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
10. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
11. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... to the American Cancer Association, prostate cancer affects one ... second leading cause of cancer deaths in men. When ... than 90 percent, making swift treatment key. (See ... however, can be limited and affect quality of life ...
... New Surgery Technique Impacting the Treatment of Women,s Cancers?CHICAGO, ... the fastest growing technological advances in the field of ... surgery (MIS) technique, its impact on the profession, and ... will be some of the topics discussed during the ...
Cached Medicine Technology:VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials 2Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery 2Society of Gynecologic Oncologists 40th Annual Meeting on Women's Cancer to Include Sessions on Robotics Surgery 3
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
(Date:4/16/2014)... STANFORD, Calif. Consider the marvel of the embryo. It ... and function as they multiply to become the cells of ... of the body. , Now, in a feat of reverse ... complex genetic coding that allows embryonic cells to proliferate and ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
(Date:4/15/2014)... the United States have nearly doubled since 1988, suggests new ... with obesity apparently to blame for the surge. The researchers ... hit all groups equally, with alarming increases in diabetes in ... reported in the April 15, 2014 issue of the ...
(Date:4/15/2014)... the RECIST Working Group published in the European Journal ... refined categorization of tumor response or various aspects of progression ... They found that modeling target lesion tumor growth did ... that of the other components of progression. The RECIST Working ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, ... certain heart patients will fare about the same whether ... that uses drug-coated stents to prop open clogged arteries. ... procedures, which also require much less recovery time. However, ...
... Cincinnati (UC) and Cincinnati Children,s Hospital Medical Center ... primarily to prevent rejection in organ transplant patients, ... The Multicenter International LAM Efficacy of Sirolimus ... designed to develop a therapy for this life-threatening ...
... MD, MPH, Medical Director and Principal Investigator of IMPACT ... Children,s National Medical Center, served as the Site Principal Investigator ... outcomes, specifically for inner-city children and teens. Findings from a ... were published and released in the March 17 issue of ...
... By Steven Reinberg HealthDay Reporter , ... in the United States reached an all-time low in ... percent from 2008, federal health officials report. , "There ... a statistician at the U.S. Centers for Disease Control ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... drug cytarabine work as well as the high doses that ... fewer side effects, a new Dutch study finds. Cytarabine ... along with other chemotherapy drugs and stem cell transplantation. Cytarabine ...
... It is no surprise to scientists that the largest social ... their face is fundamental to our social interactions, one of ... how our brain processes facial identity. In a ... scientists used an original approach a method that "shakes" ...
Cached Medicine News:Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 2Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 3Health News:New therapy found for rare lung disorder 2Health News:New therapy found for rare lung disorder 3Health News:Stephen J. Teach, MD, MPH, part of landmark study on pediatric asthma 2Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3Health News:Less Is More With Acute Myeloid Leukemia Drug 2Health News:Innovative technique gives vision researchers insight into how people recognize faces 2
... Control of thumb motion can be ... stroke, for persons with spinal cord injuries ... due to cerebral palsy or other motor ... positions the thumb for control and coordination. ...
... stabilizes the MP joint and the CMC joint of ... of both of the thumb joints. An excellent choice ... but who need maximum mobility for daily activities. Ideal ... thumb and for those with pain due to repetitive ...
... profile contour at the palmar crease to allow ... excellent choice to treat mild to moderate wrist ... wear following cast removal. The lightweight laminated ... fasteners provides support and compression to the wrist ...
... common site for arthritis in the hand. The ... the wrist or other joints of the thumb. ... or reduce subluxation of the CMC joint of ... without pain. Also useful for persons experiencing pain ...
Medicine Products: